Evidence map›Paper›PMID 28348010›Full record

ArticleHypertension (Dallas, Tex. : 1979)2017

Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.

Lama Ghazi, Suzanne Oparil, David A Calhoun, Chee Paul Lin, Tanja Dudenbostel

Abstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Lama GhaziFrom the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (L.G.); Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (S.O., D.A.C., T.D.); Alabama Medicine (S.O., D.A.C., T.D.) and Center for Clinical and Translational Science (C.P.L.), University of Birmingham at Alabama. lamaghazi@gmail.com.
Suzanne OparilFrom the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (L.G.); Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (S.O., D.A.C., T.D.); Alabama Medicine (S.O., D.A.C., T.D.) and Center for Clinical and Translational Science (C.P.L.), University of Birmingham at Alabama.
David A CalhounFrom the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (L.G.); Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (S.O., D.A.C., T.D.); Alabama Medicine (S.O., D.A.C., T.D.) and Center for Clinical and Translational Science (C.P.L.), University of Birmingham at Alabama.
Chee Paul LinFrom the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (L.G.); Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (S.O., D.A.C., T.D.); Alabama Medicine (S.O., D.A.C., T.D.) and Center for Clinical and Translational Science (C.P.L.), University of Birmingham at Alabama.
Tanja DudenbostelFrom the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (L.G.); Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (S.O., D.A.C., T.D.); Alabama Medicine (S.O., D.A.C., T.D.) and Center for Clinical and Translational Science (C.P.L.), University of Birmingham at Alabama.

Funding

UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Mechanisms of Refractory HypertensionR01HL113004 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OPARIL, SUZANNE · 2014 to 2018
$2.5M
NCATS NIH HHS UL1 TR001417NHLBI NIH HHS R01 HL113004NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Resistant hypertension, defined as blood pressure >140/90 mm Hg despite using ≥3 antihypertensive medications, is a well-recognized clinical entity. Patients with resistant hypertension are at an increased risk of cardiovascular disease compared with those with more easily controlled hypertension. Coronary heart disease mortality rates of younger adults are stagnating or on the rise. The purpose of our study was to characterize the phenotype and risk factors of younger patients with resistant hypertension, given the dearth of data on cardiovascular risk profile in this cohort. We conducted a cross-sectional analysis with predefined age groups of a large, ethnically diverse cohort of 2170 patients referred to the Hypertension Clinic at the University of Alabama at Birmingham. Patients (n=2068) met the inclusion criteria and were classified by age groups, that is, ≤40 years (12.7% of total cohort), 41 to 55 years (32.1%), 56 to 70 years (36.1%), and ≥71 years (19.1%). Patients aged ≤40 years compared with those aged ≥71 years had significantly earlier onset of hypertension (24.7±7.4 versus 55.0±14.1 years;

Indexed as

PhenotypeAdultAgedAged, 80 and overAge FactorsAldosteroneAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHypertensionMaleMiddle AgedObesityReninAldosteroneAntihypertensive AgentsReninSodium, Dietaryepidemiologyhypertensionphenotyperisk factorsyoung adult

Identifiers

PMID28348010
PMCPMC5402755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.